Cargando…

Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial

Low-dose tamoxifen halves recurrence in non-invasive breast cancer without significant adverse events. Some adjuvant trials with tamoxifen 20 mg/day had shown an association between low endoxifen levels (9–16 nM) and recurrence, but no association with CYP2D6 was shown in the NSABP P1 and P2 prevent...

Descripción completa

Detalles Bibliográficos
Autores principales:	DeCensi, Andrea, Johansson, Harriet, Helland, Thomas, Puntoni, Matteo, Macis, Debora, Aristarco, Valentina, Caviglia, Silvia, Webber, Tania Buttiron, Briata, Irene Maria, D’Amico, Mauro, Serrano, Davide, Guerrieri-Gonzaga, Aliana, Bifulco, Ersilia, Hustad, Steinar, Søiland, Håvard, Boni, Luca, Bonanni, Bernardo, Mellgren, Gunnar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994552/ https://www.ncbi.nlm.nih.gov/pubmed/33767162 http://dx.doi.org/10.1038/s41523-021-00236-6

Ejemplares similares

Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide
por: Gjerde, Jennifer, et al.
Publicado: (2012)

Inflammatory and Metabolic Biomarker Assessment in a Randomized Presurgical Trial of Curcumin and Anthocyanin Supplements in Patients with Colorectal Adenomas
por: Macis, Debora, et al.
Publicado: (2023)

Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia
por: DeCensi, Andrea, et al.
Publicado: (2019)

A Novel Automated Immunoassay Platform to Evaluate the Association of Adiponectin and Leptin Levels with Breast Cancer Risk
por: Macis, Debora, et al.
Publicado: (2021)

Taste and Smell Disorders in Cancer Treatment: Results from an Integrative Rapid Systematic Review
por: Buttiron Webber, Tania, et al.
Publicado: (2023)

Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients
por: Helland, Thomas, et al.
Publicado: (2017)

Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial
por: DeCensi, Andrea, et al.
Publicado: (2014)

First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother: a case study
por: Peccatori, Fedro Alessandro, et al.
Publicado: (2020)

Low Z‐4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen
por: Helland, Thomas, et al.
Publicado: (2020)

Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer
por: Helland, Thomas, et al.
Publicado: (2021)

A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer
por: Serrano, Davide, et al.
Publicado: (2013)

Association of Vitamin D Receptor and Vitamin D-Binding Protein Polymorphisms with Familial Breast Cancer Prognosis in a Mono-Institutional Cohort
por: Aristarco, Valentina, et al.
Publicado: (2021)

Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites
por: Chen, Yuanhuang, et al.
Publicado: (2021)

Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art
por: Provinciali, Nicoletta, et al.
Publicado: (2022)

Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment
por: Lien, Ernst A., et al.
Publicado: (2013)

Vitamin D Supplementation and Adherence to World Cancer Research Fund (WCRF) Diet Recommendations for Colorectal Cancer Prevention: A Nested Prospective Cohort Study of a Phase II Randomized Trial
por: Serrano, Davide, et al.
Publicado: (2023)

The Active Tamoxifen Metabolite Endoxifen (4OHNDtam) Strongly Down-Regulates Cytokeratin 6 (CK6) in MCF-7 Breast Cancer Cells
por: Helland, Thomas, et al.
Publicado: (2015)

Novel Treatments for Obesity: Implications for Cancer Prevention and Treatment
por: Cuttica, Carla Micaela, et al.
Publicado: (2023)

The effect of metformin on apoptosis in a breast cancer presurgical trial
por: Cazzaniga, M, et al.
Publicado: (2013)

The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial
por: Lazzeroni, M, et al.
Publicado: (2008)

A Presurgical Study of Curcumin Combined with Anthocyanin Supplements in Patients with Colorectal Adenomatous Polyps
por: Briata, Irene Maria, et al.
Publicado: (2021)

Home Se-Cure: A Home Care Service for Cancer Patients during the COVID-19 Pandemic
por: Buttiron Webber, Tania, et al.
Publicado: (2021)

The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients
por: Petrera, Marilena, et al.
Publicado: (2018)

Response to Braillon
por: Bonanni, Bernardo, et al.
Publicado: (2021)

Role of traditional and new biomarkers in breast carcinogenesis
por: Macis, D, et al.
Publicado: (2009)

Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer
por: Torrisi, R, et al.
Publicado: (2001)

Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment
por: Buttiron Webber, Tania, et al.
Publicado: (2021)

Prescribing tamoxifen in primary care for the prevention of breast cancer: a national online survey of GPs’ attitudes
por: Smith, Samuel G, et al.
Publicado: (2017)

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
por: Gjerde, Jennifer, et al.
Publicado: (2010)

Low-Dose Aspirin in High-Risk Individuals With Screen-Detected Subsolid Lung Nodules: A Randomized Phase II Trial
por: Bonanni, Bernardo, et al.
Publicado: (2020)

The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients
por: Egeland, Nina G., et al.
Publicado: (2015)

Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake
por: DeCensi, Andrea, et al.
Publicado: (2015)

Fenretinide (4-HPR): A Preventive Chance for Women at Genetic and Familial Risk?
por: Cazzaniga, Massimiliano, et al.
Publicado: (2012)

Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype
por: Lazzeroni, M, et al.
Publicado: (2013)

Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients
por: Bertelsen, Bjørn-Erik, et al.
Publicado: (2021)

The Italian Tamoxifen Prevention Trial
por: Bonanni, B., et al.
Publicado: (1999)

Breast ductal lavage for biomarker assessment in high risk women: rationale, design and methodology of a randomized phase II clinical trial with nimesulide, simvastatin and placebo
por: Lazzeroni, Matteo, et al.
Publicado: (2012)

A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer
por: Defferrari, Carlotta, et al.
Publicado: (2012)

Colorectal cancer, Vitamin D and microbiota: A double-blind Phase II randomized trial (ColoViD) in colorectal cancer patients
por: Bellerba, Federica, et al.
Publicado: (2022)

Tamoxifen reduces plasma homocysteine levels in healthy women.
por: Cattaneo, M., et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_e4ru0g3ets1q6dc7oq2kr73d44